Navigation Links
Quest Diagnostics Launches Simplexa™ Dengue Test in Brazil, First Commercial Molecular Test Approved for Nation's Public and Private Health Testing
Date:12/6/2011

MADISON, N.J. and CYPRESS, Calif., Dec. 6, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ Dengue molecular test kit developed by its Focus Diagnostics products business has been registered for distribution in Brazil.  The test kit, from the award-winning Simplexa product line on the 3M™ Integrated Cycler, is the first commercial real-time polymerase chain reaction (RT-PCR) test to be approved for use by Brazil's public and private health laboratories for testing for Dengue viruses. 

In Brazil, only test kits registered with the National Agency of Sanitary Vigilance, an office of Brazil's federal government, can be used by public or private health labs for clinical testing of patient specimens. Major public reference and private laboratories in the country are now evaluating the test for use on patient specimens.

Dengue, a virus transmitted by the Aedes mosquito, is endemic throughout the tropics and subtropics. Brazil has the greatest number of dengue infections in the Americas, with nearly a million cases annually accounting for 60 percent of the region's dengue infections. 

"Dengue is a major source of illness in Brazil and a burden on the country's healthcare system," said John G. Hurrell, Ph.D., vice president and general manager, Focus Diagnostics. "Public health and private clinicians in Brazil now have, for the first time, a registered commercial molecular-based tool for testing specimens in their own molecular laboratories. A reliable solution that can quickly identify patients with primary or secondary dengue infections will help physicians improve clinical management of patients in dengue-endemic areas."

Simplexa tests on the 3M™ Integrated Cycler employ RT-PCR to qualitatively and quantitatively detect viruses, bacteria and other agents. The Dengue test is performed on whole blood specimens to quantitatively detect and differentiate between the four Dengue serotypes (viruses DEN1-4). Results can be provided in as few as 60 minutes following sample extraction.

Dengue symptoms range from mild fever to severe headaches with muscle and joint pain.  Dengue hemorrhagic fever is a potentially fatal complication primarily affecting children.  Although there are no specific antiviral medicines for Dengue, "early clinical diagnosis and careful clinical management by experienced physicians and nurses increase survival of patients," according to the World Health Organization (WHO). The use of RT-PCR for dengue detection and differentiation allows clinicians to identify the presence of the virus, potentially enhancing clinical outcomes.

Up to 50 million dengue infections occur worldwide every year, according to estimates by the WHO.

About Simplexa

Focus Diagnostics, a wholly-owned business of Quest Diagnostics, develops and manufactures the Simplexa line of molecular test products operating on the 3M Integrated Cycler, a compact, portable testing platform, as part of an exclusive global collaboration with 3M™. Simplexa was the first test kit to be FDA cleared for aiding in the detection and differentiation of the 2009 H1N1 influenza virus, in May 2010. Additional FDA-cleared Simplexa tests aid the detection of influenza A and B and respiratory syncytial virus. Several other Simplexa-branded tests, including for Clostridium difficile, CMV, Epstein Barr and BK viruses, are CE marked and distributed in Europe. In 2011, the Simplexa/3M technology won a gold Medical Design Excellence Award in the in vitro diagnostics category and an Edison Award for new science and medical diagnostic product.

To learn more about or to order Simplexa and other Focus Diagnostics tests, please contact Focus Diagnostics at 800-445-0185 (U.S.) or +49-6026-9499540 (Europe), or visit SimplexaDx.com or FocusDx.com.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.

Contacts:
Wendy Bost (Media): 973-520-2800
Kathleen Valentine (Investors): 973-520-2900


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEOs Present and Take Questions Live, Online, December 1st at RetailInvestorConferences.com
2. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
3. Quest Diagnostics to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
5. Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe
6. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
7. Questcor Reports Third Quarter Financial Results
8. Alquest Announced as MedNet Solutions First iMedNet CRO Partner
9. Quest Introduces Its Next Generation AlphaView 4MP Medical LCD
10. Quest Diagnostics to Release Third Quarter 2011 Financial Results
11. Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016  It,s time for an upgrade. There are many medical recorders ... 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix ... a world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... Level 10 Head ... her verbal commitment to the University of Arizona for the fall of 2019. ... decision last month. Brovedani’s commitment to the GymCats came from her connection with the ...
(Date:5/4/2016)... ... ... The Spiritual Care Association (SCA) has declared May 10, 2016 ... and their families, and their overall contribution to the health care system. It will ... sent “Thank You Chaplain” cards with hand-painted artwork to about 10,000 chaplains and pastoral ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star Insurance of ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Momsense, Inc. ... The company’s patented technology, The Smart Breastfeeding Meter, is designed to monitor and ... technology is now available for purchase at Target.com . , Breastfeeding ...
(Date:5/4/2016)... Plainsboro, NJ (PRWEB) , ... May 04, 2016 ... ... for pharmacists and the pharmacy industry, today announced that it was chosen as ... Purchasing Alliance (APPA) Industry Awards . The awards acknowledge the hard work and ...
Breaking Medicine News(10 mins):